HC Wainwright restated their neutral rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q3 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.40) EPS and Q3 2027 earnings at $0.45 EPS.
Several other equities analysts have also recently issued reports on EYPT. Stifel Nicolaus began coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings raised Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Citigroup reduced their target price on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Cantor Fitzgerald cut Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $21.85.
Check Out Our Latest Research Report on Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals Stock Performance
Shares of NASDAQ EYPT opened at $0.43 on Tuesday. The firm’s 50 day moving average price is $3.99 and its 200-day moving average price is $10.03. The company has a market cap of $36.91 million, a PE ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $19.11.
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts forecast that Eyepoint Pharmaceuticals will post -3.50 earnings per share for the current fiscal year.
Institutional Trading of Eyepoint Pharmaceuticals
A number of large investors have recently made changes to their positions in EYPT. Commodore Capital LP purchased a new position in shares of Eyepoint Pharmaceuticals during the first quarter valued at approximately $36,414,000. Hsbc Holdings PLC purchased a new stake in Eyepoint Pharmaceuticals in the first quarter worth approximately $10,743,000. Janus Henderson Group PLC boosted its holdings in Eyepoint Pharmaceuticals by 22.6% in the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the last quarter. Stempoint Capital LP boosted its holdings in Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Eyepoint Pharmaceuticals in the 1st quarter worth approximately $3,869,000. 99.41% of the stock is currently owned by institutional investors.
Eyepoint Pharmaceuticals News Roundup
Here are the key news stories impacting Eyepoint Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
- Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
- Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
- Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
- Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
- Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.
EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.
See Also
- Five stocks we like better than Eyepoint Pharmaceuticals
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
